Literature DB >> 20067811

Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.

Ayele H Negussie1, Jenna L Miller, Goutham Reddy, Steven K Drake, Bradford J Wood, Matthew R Dreher.   

Abstract

The Asn-Gly-Arg (NGR) motif in both cyclic and linear form has previously been shown to specifically bind to CD13/aminopeptidase N that is selectively overexpressed in tumor vasculature and some tumor cells. However, previous versions of cyclic NGR used a liable disulfide bridge between cysteine residues that may be problematic for liposome targeting due to disulfide bond formation between adjacent peptides on the liposomal surface. In this study, we report the design, synthesis, and characterization of a novel cyclic NGR-containing peptide, cKNGRE, which does not contain a disulfide bridge. cKNGRE was synthesized in good yield and purity and attached to the fluorescent reporter Oregon Green (cKNGRE-OG) and lysolipid-containing temperature sensitive liposomes (LTSLs). The identity of cKNGRE was verified with NMR and mass spectral techniques. In vitro fluorescence microscopy evaluation of cKNGRE-OG demonstrated binding and active uptake by CD13(+) cancer cells and minimal binding to CD13(-) cancer cells. The cKNGRE-OG ligand displayed 3.6-fold greater affinity for CD13(+) cancer cells than a linear NGR-containing peptide. Affinity for CD13(+) cancer cells was similarly improved 10-fold for both the cyclic and linear NGR when presented in a multivalent fashion on the surface of an LTSL. cKNGRE-targeted LTSLs rapidly released (>75% in <4s) doxorubicin at 41.3 degrees C with minimal release at 37 degrees C. These results demonstrate the ability to synthesize a cKNGRE-targeted temperature sensitive liposome that lacks a disulfide bridge and has sufficient binding affinity for biological applications. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067811      PMCID: PMC2847670          DOI: 10.1016/j.jconrel.2009.12.031

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  53 in total

Review 1.  Integrin antagonists.

Authors:  G P Curley; H Blum; M J Humphries
Journal:  Cell Mol Life Sci       Date:  1999-10-30       Impact factor: 9.261

Review 2.  Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.

Authors:  C C Kumar; L Armstrong; Z Yin; M Malkowski; E Maxwell; H Ling; B Yaremko; M Liu; J Varner; E M Smith; B Neustadt; T Nechuta
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

3.  Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.

Authors:  S A Mousa; J M Bozarth; U P Naik; A Slee
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

4.  GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide.

Authors:  G Pagnan; P G Montaldo; F Pastorino; L Raffaghello; M Kirchmeier; T M Allen; M Ponzoni
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

5.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

Authors:  R Pasqualini; E Koivunen; R Kain; J Lahdenranta; M Sakamoto; A Stryhn; R A Ashmun; L H Shapiro; W Arap; E Ruoslahti
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

6.  Anti-cancer activity of targeted pro-apoptotic peptides.

Authors:  H M Ellerby; W Arap; L M Ellerby; R Kain; R Andrusiak; G D Rio; S Krajewski; C R Lombardo; R Rao; E Ruoslahti; D E Bredesen; R Pasqualini
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

7.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.

Authors:  A Gabizon; A T Horowitz; D Goren; D Tzemach; F Mandelbaum-Shavit; M M Qazen; S Zalipsky
Journal:  Bioconjug Chem       Date:  1999 Mar-Apr       Impact factor: 4.774

8.  Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

Authors:  F Curnis; A Sacchi; L Borgna; F Magni; A Gasparri; A Corti
Journal:  Nat Biotechnol       Date:  2000-11       Impact factor: 54.908

9.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.

Authors:  G Kong; R D Braun; M W Dewhirst
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

Review 10.  Hyperthermia and liposomes.

Authors:  G Kong; M W Dewhirst
Journal:  Int J Hyperthermia       Date:  1999 Sep-Oct       Impact factor: 3.914

View more
  32 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

2.  Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound.

Authors:  Ayele H Negussie; Pavel S Yarmolenko; Ari Partanen; Ashish Ranjan; Genevieve Jacobs; David Woods; Henry Bryant; David Thomasson; Mark W Dewhirst; Bradford J Wood; Matthew R Dreher
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

3.  Synthesis of novel cyclic NGR/RGD peptide analogs via on resin click chemistry.

Authors:  Belhu B Metaferia; Matthew Rittler; Jinesh S Gheeya; Albert Lee; Heidi Hempel; Alberto Plaza; William G Stetler-Stevenson; Carole A Bewley; Javed Khan
Journal:  Bioorg Med Chem Lett       Date:  2010-10-21       Impact factor: 2.823

4.  Effects of doxorubicin-encapsulating AG73 peptide-modified liposomes on tumor selectivity and cytotoxicity.

Authors:  Yoichi Negishi; Nobuhito Hamano; Daiki Omata; Azusa Fujisawa; Maya Manandhar; Motoyoshi Nomizu; Yukihiko Aramaki
Journal:  Results Pharma Sci       Date:  2011-10-13

5.  Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.

Authors:  Xin-Jun Cai; Wei-Dong Fei; Ying-Ying Xu; Hong Xu; Gao-Yi Yang; Jia-Wei Cao; Jian-Jun Ni; Zeng Wang
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

6.  Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).

Authors:  Brandon Smith; Ilya Lyakhov; Kristin Loomis; Danielle Needle; Ulrich Baxa; Amichai Yavlovich; Jacek Capala; Robert Blumenthal; Anu Puri
Journal:  J Control Release       Date:  2011-04-09       Impact factor: 9.776

Review 7.  Molecular theranostics: a primer for the imaging professional.

Authors:  Daniel Y Lee; King C P Li
Journal:  AJR Am J Roentgenol       Date:  2011-08       Impact factor: 3.959

8.  Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy.

Authors:  Sjoerd Hak; Jana Cebulla; Else Marie Huuse; Catharina de L Davies; Willem J M Mulder; Henrik B W Larsson; Olav Haraldseth
Journal:  Angiogenesis       Date:  2013-08-27       Impact factor: 9.596

Review 9.  Receptor-targeted nanocarriers for therapeutic delivery to cancer.

Authors:  Bo Yu; Heng Chiat Tai; Weiming Xue; L James Lee; Robert J Lee
Journal:  Mol Membr Biol       Date:  2010-10       Impact factor: 2.857

10.  Development of NGR peptide-based agents for tumor imaging.

Authors:  Rongsheng E Wang; Youhong Niu; Haifan Wu; Mohamad Nassir Amin; Jianfeng Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.